Analysis of Complex Absorption After Multiple Dosing: Application to the Interaction Between the P-glycoprotein...

Area of Science:

• Pharmacokinetics
• Drug Metabolism
• Gastrointestinal Physiology

Background:

• Talinolol is a P-glycoprotein substrate, and its bioavailability can be influenced by drug interactions.
• Rifampicin is known to induce P-glycoprotein, potentially affecting the absorption of its substrates.
• Understanding these interactions is crucial for optimizing drug therapy.

Purpose of the Study:

• To investigate the effect of rifampicin on the oral bioavailability and absorption kinetics of talinolol.
• To model the absorption process of talinolol after multiple-dose administration.
• To determine if rifampicin alters the fraction absorbed or the rate of absorption of talinolol.

Main Methods:

• A pharmacokinetic model using two inverse Gaussian functions was employed.
• The model estimated the time course of talinolol input into the systemic circulation.
• Data were collected from healthy subjects receiving multiple oral doses of talinolol with and without rifampicin.

Main Results:

• Rifampicin did not significantly alter the overall bioavailability (fraction absorbed) of talinolol.
• Rifampicin shifted the second absorption peak of talinolol from 3.5 h to 4.8 h post-administration.
• Elimination clearance and one intercompartmental clearance increased significantly during rifampicin treatment.

Conclusions:

• Rifampicin modifies the absorption rate profile of talinolol but not the extent of absorption.
• The pharmacokinetic model suggests the presence of two distinct intestinal absorption windows for talinolol.
• These findings highlight the complex interplay between P-glycoprotein, rifampicin, and talinolol absorption dynamics.